**Abstract**

**Objective:** Prolonged-release formulation of melatonin (PRM) is approved for insomnia patients ≥ 55 years old. Taking PRM 1--2 hours before bedtime is recommended, and a 26 \~ 47% response rate was reported in France and UK. Our study purpose is to investigate the effectiveness of PRM when used for insomnia patients whose sleep schedule was set.

**Method:** We reviewed the medical records of primary insomnia patients prescribed PRM after visiting the Psychiatry Department sleep clinic, Asan Medical Center, to obtain routinely asked information regarding sleep satisfaction, sleep-time schedule, and class and dose of sleeping pills. We selected patients who were dissatisfied with their sleep even after their sleep schedule was set before taking PRM. We analyzed satisfaction rate and treatment-emergent adverse events (TEAE) after taking PRM.

**Results:** Among 26 of these patients, 22 (87%) took other sleeping pills. Mean duration of taking PRM among 24 patients who were followed was 28.0 ± 13.0 days. At study endpoint, satisfaction rate to PRM was 71% (n=17) and daytime sleepiness (n=2), headache (n=1), and dizziness (n=1) were reported as TEAE. Among 20 patients who were also prescribed other sleeping pills and followed-up, 40% (n=8) could reduce their sleeping pills dosage more than 50%.

**Conclusion:** We observed a 71% satisfaction rate to PRM when we prescribed it to patients who were dissatisfied with sleep even after their sleep schedule was set. TEAE were not prevalent and 40% of patients who simultaneously took other sleeping pills could reduce the dosage. It is important to select patients who can be well-improved when PRM is prescribed for them.
